Drug eluting stents in patients with diabetes

BMJ

Volumn 337, Issue 7671, 2008, Pages 643-644

  Agostoni, Pierfrancesco ^a   Van Den Branden, Frank ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; ANTITHROMBOCYTIC AGENT;

ANTICOAGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; EDITORIAL; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MORTALITY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; REIMBURSEMENT; RESTENOSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; DIABETIC ANGIOPATHY; META ANALYSIS; NOTE; RANDOMIZED CONTROLLED TRIAL;

CORONARY RESTENOSIS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 51649106210     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a1359     Document Type: Editorial

References (9)

1. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005;293:1501-8.
2. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008;52:255-62.
3. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, et al. Drug eluting and bare metal stents in patients with and without diabetes: collaborative network meta-analysis. BMJ 2008;337:a1331.
4. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55.
5. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 2007;356:325-8.
6. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97.
7. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008;51:708-15.
8. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, et al, EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT matched-cohort registry. J Am Coll Cardiol 2007;50:501-8.
9. National Institute for Health and Clinical Excellence. Coronary artery disease - drug-eluting stents. 2008. www.nice.org.uk/guidance/index.jsp? action=byID&o=12013.